Seretide: A pharmacoeconomic analysis

Journal of Medical Economics

Volumn 11, Issue 3, 2008, Pages 555-570

  Fritscher, Leandro ^a   Chapman, Kenneth R ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Advair; Asthma; COPD; Costs; Fluticasone; Inhaled corticosteroids; Long acting 2 agonists; Pharmacoeconomic; Salmeterol

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CORTICOSTEROID; DISKUS; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; LEUKOTRIENE DERIVATIVE; PLACEBO; SALMETEROL; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG;

ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG MEGADOSE; HEALTH CARE COST; HUMAN; LUNG FUNCTION; MAINTENANCE THERAPY; MONOTHERAPY; MORTALITY; QUALITY OF LIFE; REVIEW; SURVIVAL RATE; SYSTEMATIC REVIEW;

ALBUTEROL; ANDROSTADIENES; ASTHMA; BRONCHODILATOR AGENTS; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY-ADJUSTED LIFE YEARS;

EID: 55049114522     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696990802320908     Document Type: Review

References (73)

1. Chapman KR, Ernst P, Grenville A, Dewland P, Zimmerman S. Control of asthma in Canada: Failure to achieve guideline targets. Canadian Respiratory Journal 2001; 8(Suppl A): 35A-40A.
2. Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. European Respiratory Journal 2000; 16(5): 802-807.
3. Lai CKW, De Guia TS, Kim YY et al. Asthma control in the Asia-Pacific region: The asthma insights and reality in Asia-Pacific study. Journal of Allergy & Clinical Immunology 2003; 111(2): 263-268.
4. Adachi M, Morikawa A, Ishihara K. [Asthma insights & reality in Japan (AIRJ)]. Arerugi 2002; 51(5):411-420.
5. Braman SS. The global burden of asthma. Chest 2006; 130(1 Suppl.): 4S-12S.
6. Beasley R. The burden of asthma with specific reference to the United States. Journal of Allergy & Clinical Immunology 2002; 109(5 Suppl.): S482-S489.
7. Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. European Respiratory Journal 2000; 16(5): 802-807.
8. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. Available at: http://www.goldcopd.com.
9. Chapman KR, Mannino DM, Soriano JB et al. Epidemiology and costs of chronic obstructive pulmonary disease. European Respiratory Journal 2006; 27(1): 188-207.
10. Lokke A, Lange P, Scharling H, Fabricius P, Vestbo J. Developing COPD: a 25 year follow up study of the general population. Thorax 2006; 61(11): 935-939.
11. Miravitlles M, Ferrer M, Pont A et al. Characteristics of a population of COPD patients identified from a population-based study. Focus on previous diagnosis and never smokers. Respiratory Medicine 2005; 99(8): 985-995.
12. Kesten S, Chapman KR. Physician perceptions and management of COPD. Chest 1993; 104: 254-258.
13. Chapman KR, Tashkin DP, Pye DJ. Gender bias in the diagnosis of COPD. Chest 2001; 119(6): 1691-1695.
14. Soriano JB, Maier WC, Egger P et al. Recent trends in physician diagnosed COPD in women and men in the UK. Thorax 2000; 55(9): 789-794.
15. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance - United States, 1971-2000. Respiratory Care 2002; 47(10): 1184-1199.
16. Chapman KR. Chronic obstructive pulmonary disease: are women more susceptible than men? Clinical Chest Medicine 2004; 25(2): 331-341.
17. Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004; 59(5): 469-478.
18. Braman SS. The global burden of asthma. Chest 2006; 130(1 Suppl.): 4S-12S.
19. Chapman KR. Impact of 'mild' asthma on health outcomes: findings of a systematic search of the literature. Respiratory Medicine 2005; 99(11): 1350-1362.
20. Sorensen L, Weng S, Weng S, Wulf-Andersen L, Ostergaard D, Bech P. The costs of asthma in Denmark. British Journal of Medical Economics 1997; 11: 103-111.
21. Chapman KR. Impact of 'mild' asthma on health outcomes: findings of a systematic search of the literature. Respiratory Medicine 2005; 99(11): 1350-1362.
22. Halpin DM, Miravitlles M. Chronic obstructive pulmonary disease: the disease and its burden to society. Proceedings of the American Thoracic Society 2006; 3(7): 619-623.
23. Britton M. The burden of COPD in the U.K.: results from the Confronting COPD survey. Respiratory Medicine 2003; 97(Suppl. C): S71-S79.
24. Wouters EF. Economic analysis of the Confronting COPD survey: an overview of results. Respiratory Medicine 2003; 97(Suppl. C): S3-S14.
25. National Heart LaBI, National Institutes of Health, World Health Organization. Global Intitiave for Asthma. Available at: http://www.ginasthma.com.
26. Chapman KR. Impact of 'mild' asthma on health outcomes: findings of a systematic search of the literature. Respiratory Medicine 2005; 99(11): 1350-1362.
27. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 1994; 344(8917): 219-224.
28. Pauwels RA, Lofdahl CG, Postma DS et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. New England Journal of Medicine 1997; 337(20):1405-1411.
29. Matz J, Emmett A, Rickard K, Kalberg C. Addition of salmeterol to low-dose fluticasone versus higher-dose fluticasone: An analysis of asthma exacerbations. Journal of Allergy & Clinical Immunology 2001; 107(5): 783-789.
30. Bateman ED, Boushey HA, Bousquet J et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. American Journal of Respiratory Critical Care Medicine 2004; 170(8): 836-844.
31. Mahler DA, Donohue JF, Barbee RA et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115(4): 957-965.
32. Rennard SI, Anderson W, ZuWallack R et al. Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease, American Journal of Respiratory Critical Care Medicine 2001; 163(5): 1087-1092.
33. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. British Medical Journal 2000; 320(7245): 1297-1303.
34. Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet 1998; 351(9105): 773-780.
35. Sin DD, Tu JV. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. American Journal of Respiratory Critical Care Medicine 2001; 164(4): 580-584.
36. Sin DD, Wu L, Anderson JA et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 2005; 60(12): 992-997.
37. Price MJ, Briggs AH. Development of an economic model to assess the cost effectiveness of asthma management strategies. Pharmacoeconomics 2002; 20(3): 183-194.
38. Pieters W, Lundback B, Sondi S. Cost-effectiveness analyses of salmeterol/fluticasone propionate 50/500μg vs fluticasone propionate 500μg in adults and adolescents with asthma. Pharmacoeconomics 1999; 16(Suppl. 2): 29-34.
39. Palmqvist M, Price M, Sondi S. Cost-effectiveness analysis of salmeterol/ fluticasone propionate 50/250μg vs fluticasone propionate 250μg in adults and adolescents with asthma. IV results. Pharmacoeconomics 1999; 16(Suppl. 2): 23-28.
40. Johansson G, Price MJ, Sondhi S. Cost-effectiveness analysis of salmeterol/fluticasone propionate 50/100μg vs fluticasone propionate 100μg in adults and adolescents with asthma. III: results. Pharmacoeconomics 1999; 16(Suppl. 2):15-21.
41. Price M, Briggs A, Williams J. Development of an economic model to evaluate the cost-effectiveness of treatments in achieving asthma control. American Journal of Respiratory Critical Care Medicine 2001; 163(5 Suppl. Pt 2): A505.
42. Chew F, Lim T, Lee B. Cost-effectiveness analyses comparing Seretide (salmeterol/fluticasone propionate combination product) and budesonide for the treatment of asthma in Singapoure. European Respiratory Journal 2000; 16(Suppl. 31): 456s.
43. Lundback B, Jenkins C, Price MJ. Cost-effectiveness of salmeterol/ fluticasone propionate combination product 50/250ug twice daily and budesonide 800ug twice daily in the treatment of adults and adolescents with asthma. Respiratory Medicine 2000; 94: 724-732.
44. Pieters WR, Wilson KK, Smith HC, Tamminga JJ, Sondhi S. Salmeterol/ fluticasone propionate versus fluticasone propionate plus montelukast: a cost-effective comparison for asthma. Treatments in Respiratory Medicine 2005; 4(2): 129-138.
45. O'Connor RD, Nelson H, Borker R et al. Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma. Pharmacoeconomics 2004; 22(12): 815-825.
46. O'Connor RD, O'Donnell JC, Pinto LA, Wiener DJ, Legorreta AP. Two-year retrospective economic evaluation of three dual-controller therapies used in the treatment of asthma. Chest 2002; 121(4): 1028-1035.
47. Delea T, Stanford R, Hagiwara M, Oster G. Outcomes and costs in patients with asthma receiving inhaled corticosteroids who switch to fluticasone propionate/salmeterol as a single inhaler or add-on salmeterol from a separate inhaler or add-on montelukast. Proceedings of the American Thoracic Society 2005: 2.
48. Bateman ED, Boushey HA, Bousquet J et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. American Journal of Respiratory Critical Care Medicine 2004; 170(8): 836-844.
49. Briggs AH, Bousquet J, Wallace MV et al. Cost-effectiveness of asthma control: an economic appraisal of the GOAL study. Allergy 2006; 61(5): 531-536.
50. Godard P, Chanez P, Siraudin L, Nicoloyannis N, Duru G. Costs of asthma are correlated with severity: a 1-yr prospective study. European Respiratory Journal 2002; 19(1): 61-67.
51. Chapman KR. Impact of 'mild' asthma on health outcomes: findings of a systematic search of the literature. Respiratory Medicine 2005; 99(11): 1350-1362.
52. Chapman KR. Impact of 'mild' asthma on health outcomes: findings of a systematic search of the literature. Respiratory Medicine 2005; 99(11): 1350-1362.
53. Fuhlbrigge AL, Adams RJ, Guilbert TW et al. The burden of asthma in the United States: level and distribution are dependent on interpretation of the national asthma education and prevention program guidelines. American Journal of Respiratory Critical Care Medicine 2002; 166(8): 1044-1049.
54. Godard P, Chanez P, Siraudin L, Nicoloyannis N, Duru G. Costs of asthma are correlated with severity: a 1-yr prospective study. European Respiratory Journal 2002; 19(1): 61-67.
55. Erickson SR, Christian RD Jr. Kirking DM, Halman LJ. Relationship between patient and disease characteristics, and health-related quality of life in adults with asthma. Respiratory Medicine 2002; 96(6): 450-460.
56. Keech M, Bridge S, Kennedy-Martin T. Even patients with mild asthma lose time from work due to uncontrolled asthma. American Journal of Respiratory Critical Care Medicine 2004; 169(7): A363.
57. Williams AE, Watson L, Kennedy-Martin T, Rabe K. The burden of unscheduled health care resource use in asthma is significant: asthma Insights and Reality in Europe (AIRE) survey. American Journal of Respiratory Critical Care Medicine 2004; 169(7): A330.
58. Barnes PJ, Jonsson B, Klim JB. The costs of asthma. European Respiratory Journal 1996; 9(4): 636-642.
59. Barnes NC, Williams AE. Unscheduled healthcare resource use among asthma patients receiving low-dose inhaled corticosteroids maintenance treatment. International Journal of Clinical Practice 2005; 59(9): 1017-1024.
60. Riedel A, Harley C, Stempel D, Stanford R. Treatment failure is reduced in patients initiating therapy with fluticasone propionate/salmeterol in a single inhaler as compared with other inhaled corticosteroid asthma treatments. Journal of Allergy & Clinical Immunology 2005; 115(2): S2.
61. Borker R, Emmett A, Jhingran P, Rickard K, Dorinsky P. Determining economic feasibility of fluticasone propionate-salmeterol vs montelukast in the treatment of persistent asthma using a net benefit approach and cost-effectiveness acceptability curves. Annals of Allergy & Asthma Immunology 2005; 95(2): 181-189.
62. Sheth K, Borker R, Emmett A, Rickard K, Dorinsky P. Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma. Pharmacoeconomics 2002; 20(13): 909-918.
63. Bateman ED, Jacques L, Goldfrad C, Atienza T, Mihaescu T, Duggan M. Asthma control can be maintained when fluticasone propionate/salmeterol in a single inhaler is stepped down. Journal of Allergy & Clinical Immunology 2006; 117(3): 563-570.
64. Sin DD, McAlister FA, Man SF, Anthonisen NR. Contemporary management of chronic obstructive pulmonary disease: scientific review. Journal of the American Medical Association 2003; 290(17): 2301-2312.
65. Anzueto A, McLaughlin T, Stanford RH. Initial treatment regimen and risk of hospitalization in patients with chronic obstructive pulmonary disease. Chronic Obstructive Pulmonary Disease 2004; 1(2): 205-214.
66. Gagnon YM, Levy AR, Spencer MD et al. Economic evaluation of treating chronic obstructive pulmonary disease with inhaled corticosteroids and long-acting beta2-agonists in a health maintenance organization. Respiratory Medicine 2005; 99(12): 1534-1545.
67. Punekar Y, Gulsvik A, Istad J-A, Spencer M. Estimating cost-effectiveness of Seretide in COPD as cost per quality adjusted life year (QALY). European Respiratory Journal 2004; 24(Suppl. 48): 16s.
68. Calverley P, Pauwels R, Vestbo J et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361(9356): 449-456.
69. Spencer M, Briggs AH, Grossman RF, Rance L. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics 2005; 23(6): 619-637.
70. Aaron SD, Vandemheen KL, Fergusson D et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine 2007; 146(8): 545-555.
71. Calverley PM, Anderson JA, Celli B et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine 2007; 356(8): 775-789.
72. Glick H, Briggs A, Lozano-Ortega G, Spencer M, Vestbo J, Calverley P. Is treatment with ICS/LABA combination good value for money in COPD? Evidence from the TORCH study. American Journal of Respiratory Critical Care Medicine 2007; 175(Abstr): A763.
73. National Institute for Health and Clinical Excellence (NICE). Guide to the Methods of Technology Appraisal. London: 2004.